A renaissance for SRC
The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This suggests that SRC activation may also be a dominant feature in CRC, which is supported by the observation that SRC activation was documented in > 80% of CRC [17].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [17]
In the citing paper
“In response signaling from a variety of RTKs (including EGFR, HER2, HER4, PDGFR, VEGFR, FGFR4, GPCR, C-MET, IL-4/IL13/IL-13Rα2, IL-6ST/IL-6R/IL-11R), SRC has been reported to mediate diverse cell signaling pathways including RAS/MAPK (proliferation), PI3K/AKT (survival), FAK (adhesion/migration/EMT), and STAT3 (angiogenesis) [17, 49, 50].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [17]
In the citing paper
“Aberrant SRC activation has been associated with a more aggressive phenotype and a worse prognosis in CRC patients [27, 28, 39].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [39]
In the citing paper
“The c-src is a non-receptor protein tyrosine kinase with a 60-kD molecular weight.It is a member of a 9-gene family named the Src family kinases (SFKs)”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [1]
Citations
Cites
Integrins: Versatility, modulation, and signaling in cell adhesion
Hynes, R. O. (1992) · Cell · doi:10.1016/0092-8674(92)90115-s · Cited by 9,859 · cited 1×
“Focal adhesions are also disassembled during transformation, during which the integrity of these structures is disrupted, permitting increased motilit”
BackgroundCell Migration: A Physically Integrated Molecular Process
Lauffenburger, D. A., & Horwitz, A. F. (1996) · Cell · doi:10.1016/s0092-8674(00)81280-5 · Cited by 3,915 · cited 1×
“This is followed by release of adhesions and retraction of the rear en”
BackgroundGiancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345 · cited 1×
“Although not yet reported for c- SRC , it has been possible to transform human fibroblasts with oncogenes such as HRAS when they are combined with human telomerase reverse transcriptase and the SV40 large T antige”
BackgroundTransforming gene product of Rous sarcoma virus phosphorylates tyrosine
Hunter, T., & Sefton, B. M. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1311 · Cited by 2,332 · cited 1×
“v- src was subsequently shown to encode a tyrosine-specific protein kinas”
BackgroundThe STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“STAT3 activation by v-Src has also been shown to contribute to other biological properties of cancer cells, including cell growth and survival, and tumour-cell immune evasio”
BackgroundFOCAL ADHESIONS, CONTRACTILITY, AND SIGNALING
Burridge, K., & Chrzanowska-Wodnicka, M. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.463 · Cited by 1,942 · cited 1×
“Small adhesions can transmit stong forces for rapid movement and ultimately mature into larger focal adhesion”
BackgroundReduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice
llić, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., Yamamoto, T., et al. (1995) · Nature · doi:10.1038/377539a0 · Cited by 1,830
E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells.
Frixen, U. H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Löchner, D., & Birchmeier, W. (1991) · The Journal of cell biology · doi:10.1083/jcb.113.1.173 · Cited by 1,551 · cited 1×
“Definitive studies in transgenic mice indicate that E-cadherin is an invasion suppresso”
BackgroundA causal role for E-cadherin in the transition from adenoma to carcinoma
Perl, A.-K., Wilgenbus, P., Dahl, U., Semb, H., & Christofori, G. (1998) · Nature · doi:10.1038/32433 · Cited by 1,424 · cited 1×
“and overexpression of E-cadherin can, in fact, counteract the acquisition of the invasive phenotyp”
Background
Cited by
Items 801–900 of 999
Shaji, S. K., Drishya, G., Sunilkumar, D., Suravajhala, P., Kumar, G. B., & Nair, B. G. (2022) · Scientific Reports · doi:10.1038/s41598-022-07087-6 · Cited by 12
Rapid Actions of the Nuclear Progesterone Receptor through cSrc in Cancer
Bello‐Alvarez, C., Zamora-Sánchez, C. J., & Camacho‐Arroyo, I. (2022) · Cells · doi:10.3390/cells11121964 · Cited by 13
“Unlike other proteins associated with the hallmarks of cancer, cSrc has no mutations but exhibits high enzymatic activity [12].”
BackgroundNovel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy
Sawyer, T. K. (2007) · Topics in medicinal chemistry · doi:10.1007/7355_2006_010 · Cited by 14
Foltz, L., Palacios-Moreno, J., Mayfield, M. E., Kinch, S., Dillon, J., Syrenne, J. T., Levy, T. M., & Grimes, M. L. (2020) · Molecular Biology of the Cell · doi:10.1091/mbc.e20-02-0135 · Cited by 13
“While SRC’s normal function centers around cell migration, adhesion, and receptor endocytosis (Yeatman, 2004), FYN and LYN appear to have specialized roles in differentiation.”
BackgroundShi, X., Opi, S., Lugari, A., Restouin, A., Coursindel, T., Parrot, I., Pérez, J., Madore, É., Zimmermann, P., Corbeil, J., et al. (2010) · Biochemical Journal · doi:10.1042/bj20100314 · Cited by 14
Rational Design of Multitargeted Tyrosine Kinase Inhibitors: A Novel Approach
Barchéchath, S., Williams, C., Saade, K., Lauwagie, S., & Jean‐Claude, B. J. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00786.x · Cited by 12
PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
Davis, T. B., Yang, M., Wang, H., Lee, C., Yeatman, T. J., & Pledger, W. J. (2019) · Oncotarget · doi:10.18632/oncotarget.27335 · Cited by 11
“The lack of SRC activity in cells without PTPRS was thought possibly due to increased phosphorylation of Y-530 which would negatively regulate SRC activity [15] and explain how PTPRS promoted an increase in SRC activity.”
BackgroundSelf-citationAdvances in mechanisms of resistance to aromatase inhibitors
Chumsri, S., Schech, A. J., Chakkabat, C., Sabnis, G. J., & Brodie, A. M. H. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.882233 · Cited by 14
“Besides its involvement in cell proliferation, SRC also regulates cell adhesion, invasion and motility, which contribute to tumor progression and metastasis [60].”
BackgroundBello‐Alvarez, C., Moral‐Morales, A. D., González‐Arenas, A., & Camacho‐Arroyo, I. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.640298 · Cited by 11
“However, most recent investigations have found that cSrc regulates processes such as adhesion, invasion, and motility (38, 43).”
BackgroundInfluentialAlfano, A., Xu, J., Yang, X., Deshmukh, D., & Qiu, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050932 · Cited by 12
“C-Src, the prototypical SFK, is one of the oldest known and most widely studied of all proto-oncogenes [6,7].”
BackgroundNew small molecules in dermatology: for the autoimmunity, inflammation and beyond
Criado, P. R., Lorenzini, D., Miot, H. A., Filho, R. B., Carneiro, F. R. O., & Ianhez, M. (2023) · Inflammation Research · doi:10.1007/s00011-023-01744-w · Cited by 12
Wu, W.-G., Wang, Y., Xu, Y.-Z., Liu, Y., & Zhang, H.-Z. (2014) · Placenta · doi:10.1016/j.placenta.2014.07.012 · Cited by 11
“c-Src is a non-receptor tyrosine kinase and plays essential roles in cell proliferation, survival, adhesion, morphology and motility [8,9].”
BackgroundChan, K., Lio, D. S. S., Dobson, R. C. J., Jarasrassamee, B., Hossain, M. I., Roslee, A. K., Ia, K. K., Perugini, M. A., & Cheng, H. (2010) · Protein Expression and Purification · doi:10.1016/j.pep.2010.07.007 · Cited by 11
Capurso, G., Florio, A. D., Sette, C., & Fave, G. D. (2012) · Neuroendocrinology · doi:10.1159/000336093 · Cited by 12
Fichter, C. D., Przypadlo, C. M., Buck, A., Herbener, N., Riedel, B., Schäfer, L., Nakagawa, H., Walch, A. K., Reinheckel, T., Werner, M., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4987 · Cited by 13
de Nonneville, A. T., Finetti, P., Adélaïde, J., Lambaudie, É., Viens, P., Gonçalvès, A., Birnbaum, D., Mamessier, É., & Bertucci, F. (2019) · Cancers · doi:10.3390/cancers11081158 · Cited by 11
Sergeys, J., Hove, I. V., Hu, T., Temps, C., Carragher, N. O., Unciti‐Broceta, A., Feyen, J. H. M., Moons, L., & Porcu, M. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108108 · Cited by 11
Regulatory Roles of the N-Terminal Intrinsically Disordered Region of Modular Src
Kato, G. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042241 · Cited by 12
“However, it remains possible that human oncogenesis is attributable to the deregulation of Src [103,104].”
BackgroundIsolated limb infusion as a model to test new agents to treat metastatic melanoma
Lidsky, M. E., Speicher, P. J., Jiang, B. S., Tsutsui, M., & Tyler, D. S. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23502 · Cited by 11
Ubiquitination of Src promotes its secretion via small extracellular vesicles
Tanaka, K., Ito, Y., Kajiwara, K., Nada, S., & Okada, M. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.02.057 · Cited by 11
Novel Targets for Anticancer Treatment Development in Colorectal Cancer
Macarulla, T. M., Ramos, F. J., Capdevila, J., Saura, C., & Tabernero, J. M. (2006) · Clinical Colorectal Cancer · doi:10.3816/ccc.2006.n.045 · Cited by 12
Src SUMOylation Inhibits Tumor Growth Via Decreasing FAK Y925 Phosphorylation
Wang, J., Deng, R., Cui, N., Zhang, H., Liu, T., Dou, J., Zhao, X., Chen, R., Wang, Y., Yu, J., et al. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.001 · Cited by 10
“It is about 60KD in size [2] and belongs to Src family kinases (SFKs), where other members are Yes, Fyn, Lyn, Lck, Hck, Fgr, Blk and Yrk [3].”
BackgroundMontone, R., Romanelli, M. G., Baruzzi, A., Ferrarini, F., Liboi, E., & Lievens, P. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.12.008 · Cited by 13
Cell-cell interactions that drive tumorigenesis in Drosophila
Enomoto, M., & Igaki, T. (2022) · Fly · doi:10.1080/19336934.2022.2148828 · Cited by 10
“Given that Src activity and expression are increased in cancers[54], Src-activated cells may evade cell competition during cancer progression.”
BackgroundGurumoorthy, V., Shrestha, U. R., Zhang, Q., Pingali, S. V., Boder, E. T., Urban, V. S., Smith, J. C., Petridis, L., & O’Neill, H. (2023) · Biomacromolecules · doi:10.1021/acs.biomac.2c01158 · Cited by 10
Bello‐Alvarez, C., Zamora-Sánchez, C. J., Peña‐Gutiérrez, K. M., & Camacho‐Arroyo, I. (2022) · Oncology Letters · doi:10.2139/ssrn.4063585 · Cited by 11
The Src-Family Kinases SRC and BLK Contribute to the CLDN6-Adhesion Signaling
Ichikawa‐Tomikawa, N., Sugimoto, K., Kashiwagi, K., & Chiba, H. (2023) · Cells · doi:10.3390/cells12131696 · Cited by 9
“SFKs, including SRC, are frequently activated in many types of cancers and promote cancer progression [4,8,48,49].”
BackgroundShen, Y.-Z., & TanTai, J. (2023) · Gene · doi:10.1016/j.gene.2023.147873 · Cited by 11
Dihydrotestosterone Potentiates EGF-Induced ERK Activation by Inducing SRC in Fetal Lung Fibroblasts
Lee, M. K., Smith, S. M., Murray, S., Pham, L. D., Minoo, P., & Nielsen, H. C. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0179oc · Cited by 11
“Specifically, autophosphorylation of Tyr424 in the SH1 domain (analogous to chicken Tyr416 and human Tyr419) is necessary for full activation (41).”
BackgroundLaurenzana, I., Caivano, A., Rocca, F. L., Trino, S., Luca, L. D., D’Alessio, F., Schenone, S., Falco, G., Botta, M., Vecchio, L. D., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00416 · Cited by 10
SRC fine‐tunes ADAM10 shedding activity to promote pituitary adenoma cell progression
Huang, J., Pan, Y. J., Hu, G., Sun, W., Jiang, L., Wang, P., & Ding, X. (2019) · FEBS Journal · doi:10.1111/febs.15026 · Cited by 13
Targeting SRC Family Kinases in Mesothelioma: Time to Upgrade
Indovina, P., Forte, I. M., Pentimalli, F., & Giordano, A. (2020) · Cancers · doi:10.3390/cancers12071866 · Cited by 12
“Another primary role of SFKs is to control cytoskeletal organization, cell adhesion, migration, and invasion [25,29,57–59], which are related processes requiring precisely orchestrated molecular interactions [25].”
BackgroundInfluentialCD99 inhibits CD98-mediated β1 integrin signaling through SHP2-mediated FAK dephosphorylation
Lee, K. J., Yoo, Y. H., Kim, M. S., Yadav, B. K., Kim, Y., Lim, D., Hwangbo, C., Moon, K. W., Kim, D., Jeoung, D., et al. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.07.010 · Cited by 10
Eguchi, R., Fujita, Y., Tabata, C., Ogawa, H., Wakabayashi, I., Nakano, T., & Fujimori, Y. (2015) · Oncology Reports · doi:10.3892/or.2015.4200 · Cited by 10
Guz, N. R., Leuser, H., & Goldman, E. A. (2013) · Organic Process Research & Development · doi:10.1021/op400137m · Cited by 10
Effect of saracatinib on pulmonary metastases from hepatocellular carcinoma
Xiong, J., Wu, J., Mao, S., Yu, X., & Huang, X. (2016) · Oncology Reports · doi:10.3892/or.2016.4968 · Cited by 9
Kasahara, K., Nakayama, Y., & Yamaguchi, N. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.11.025 · Cited by 10
“Among all of the SFK members, c-Src is the one that is most often implicated in cancer [2–4].”
BackgroundInfluentialTranscriptional signature induced by a metastasis‐promoting c‐Src mutant in a human breast cell line
Broecker, F., Hardt, C., Herwig, R., Timmermann, B., Kerick, M., Wunderlich, A., Schweiger, M. R., Borsig, L., Heikenwalder, M., Lehrach, H., et al. (2016) · The FEBS Journal · doi:10.1111/febs.13694 · Cited by 9
The Role of ErbB Receptors in Endometrial Cancer
Georgios, A., & Georgios, A. (2012) · InTech eBooks · doi:10.5772/26858 · Cited by 13
Beyond Expression: Role of Phosphorylated Residues of EZH2 in Lineage Plasticity in Prostate Cancer
Nouruzi, S., Tabrizian, N., & Zoubeidi, A. (2023) · Endocrinology · doi:10.1210/endocr/bqad023 · Cited by 9
Targeting CD36 determines nicotine derivative NNK-induced lung adenocarcinoma carcinogenesis
Li, M., Wang, M., Dong, M., Wu, Z., Zhang, R., Wang, B., Huang, Y., Zhang, X., Zhou, J., Yi, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107477 · Cited by 9
“The non-receptor tyrosine kinases Src family include Src (also as c-Src), Fyn, Yes, Fgr, Yrk, Lyn, Hck, Lck, and Blk, which localize within the cytosol and transduce signals between cell surface proteins and other intracellular proteins, including transcription factors.(19) 1Department of Physiology, School of Basic M…”
BackgroundTargeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories
Aliabadi, H. M., Manda, A., Sidgal, R., & Chung, C. (2023) · Biomolecules · doi:10.3390/biom13091306 · Cited by 9
“…drugs due to gaps in knowledge in its role and activation mechanisms [47]. involved in breast cancer and hyperactivated in many types of cancer, it has just recently become an attractive target for molecularly targeted drugs due to gaps in knowledge in its role and activation mechanisms [47].”
InfluentialTakahashi, M., Araki, T., Yashima, H., Nagamine, A., Nagano, D., & Yamamoto, K. (2023) · Oncology Letters · doi:10.3892/ol.2023.14116 · Cited by 10
“and c‑MET (34), and it is involved in cell proliferation and metastasis in various carcinomas (35‑37) by activation of the RAS/RAF/MEK/ERK pathway (38), PI3K/Akt/mTOR pathway (39), integrin/FAK pathway (40,41), and JAK/STAT pathway (39,40).”
BackgroundArulanandam, R., Geletu, M., & Raptis, L. H. (2010) · PubMed · Cited by 9
AHA1 regulates cell migration and invasion via the EMT pathway in colorectal adenocarcinomas
Kim, D., Moon, J. W., Min, D. H., Ko, E. S., Ahn, B., Kim, E. S., & Lee, J.-Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-99375-w · Cited by 9
Bendinelli, P., Maroni, P., Matteucci, E., & Desiderio, M. A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.06.004 · Cited by 9
“pSrc is the active form of the tyrosine kinase [44].”
Backgroundv-Src-mediated transformation suppresses the expression of focal adhesion protein vinexin
Umemoto, T., Inomoto, T., Ueda, K., Hamaguchi, M., & Kioka, N. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.017 · Cited by 9
“Src is a tyrosine kinase that is either overexpressed or activated in human cancers including breast, colorectal, and hepatocellular cancers [7–10].”
BackgroundMessina, C. G. M., Buzzatti, G., Dellepiane, C., Cavo, A., Tolomeo, F., Cattrini, C., & Boccardo, F. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000405 · Cited by 9
Manipulating PTPRD function with ectodomain antibodiesPreprint
Qian, Z., Song, D., Ipsaro, J. J., Bautista, C., Joshua‐Tor, L., Yeh, J. T. ‐., & Tonks, N. K. (2023) · Genes & Development · doi:10.1101/gad.350713.123 · Cited by 9
“In this study, we focused on a receptor tyrosine phosphatase, PTPRD, that was previously shown to promote metastasis in breast cancer models (Chaudhary et al. 2015; Yuwanita et al. 2015).”
ErbB Receptors and ErbB Targeted Therapies in Endometrial Cancer
Georgios, A., Michail, G., Adonakis, G., & Decavalas, G. (2014) · Journal of Cancer Therapy · doi:10.4236/jct.2014.56055 · Cited by 8
“4) Src Kinase pathway [40]-[43].”
Elfiky, A. A., Ibrahim, I. M., Amin, F. G., Ismail, A. M., & Elshemey, W. M. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-63761-3_10 · Cited by 12
Paik, S. J., Kim, D. J., & Jung, S. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065953 · Cited by 10
“Src, Fyn, Yes, Yrk, Blk, Fgr, Hck, Lck, and Lyn are included in SFK [14].”
BackgroundPlatek, A., Vassilev, V. S., de Diesbach, P., Tyteca, D., Mettlen, M., & Courtoy, P. J. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.01.020 · Cited by 8
The Role of Neuropilin-1–FYN Interaction in Odontoblast Differentiation of Dental Pulp Stem Cells
Song, Y., Cao, P., Gu, Z., Xiao, J., Lian, M., Huang, D., Xing, J., Zhang, Y., Feng, X., & Wang, C. (2018) · Cellular Reprogramming · doi:10.1089/cell.2017.0041 · Cited by 8
“Similar to other family members of SrcPTKs, the activity of FYN is possessed by molecular interactions affected by tyrosine phosphorylation and dephosphorylation (Yeatman, 2004).”
Visualizing Spatiotemporal Dynamics of Intercellular Mechanotransmission upon Wounding
Wang, P., Liang, J., Shi, L. Z., Wang, Y., Zhang, P., Ouyang, M., Preece, D., Qin, P., Shao, L., Fan, J., et al. (2018) · ACS Photonics · doi:10.1021/acsphotonics.8b00383 · Cited by 8
Systematic Review of Potential Anticancerous Activities of Erythrina senegalensis DC (Fabaceae)
Fofana, S., Ouédraogo, M., Esposito, R. C., Ouedraogo, W. P., Delporte, C., Antwerpen, P. V., Mathieu, V., & Guissou, I. P. (2021) · Plants · doi:10.3390/plants11010019 · Cited by 15
“Src is a well-known key oncoprotein involved in cancer cell proliferation and survival through the activation of PI3K/Akt, MAPK, and Stat3 but also in adhesion, migration and angiogenesis by modulating IL-8 and VEGF expression and cytoskeletal formation [83].”
BackgroundWang, L., Guo, B., Wang, R., Jiang, Y., Qin, S., Liang, S., Zhao, Y., Guo, W., Li, K., & Fan, X. (2011) · Clinical Science · doi:10.1042/cs20110230 · Cited by 9
Singh, S., Singh, S., & Shukla, P. (2010) · Medicinal Chemistry Research · doi:10.1007/s00044-010-9416-0 · Cited by 8
“, 2000), nelfinavir (Yeatman, 2004), amprenavir (Talamonti et al.”
BackgroundFang, F., Li, D., Li, J., Sun, J., Du, Q., Gong, H., & Zhu, H. (2013) · RSC Advances · doi:10.1039/c3ra45204b · Cited by 8
Zhang, H., Gao, B., & Shi, B. (2016) · Disease Markers · doi:10.1155/2016/2832980 · Cited by 8
Chiang, A. W. T., Wu, Y., Wang, T., & Hwang, M. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005368 · Cited by 9
Hughes, V. S., & Siemann, D. W. (2018) · Tumor and Microenvironment · doi:10.4103/tme.tme_19_17 · Cited by 9
“[8] Additionally, protein and activity levels appear to positively correlate with disease progression.[8-10] Because of the critical role that Src plays in metastasis-related signaling pathways, inhibition of its activity may offer a valuable therapeutic strategy.”
BackgroundLv, Y., Deng, H., Liu, Y., Chang, K., Du, H., Zhou, P., Mao, H., & Hu, C. (2020) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2020.103834 · Cited by 8
Spolaor, S., Scheve, M., Fırat, M., Cazzaniga, P., Besozzi, D., & Nobile, M. S. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.617935 · Cited by 10
“It plays a role in the development of several cancer types, and its inhibition (“Src is low”) is known to be effective in stopping cancer cell proliferation (Yeatman, 2004).”
BackgroundKim, Y.-K., Ahn, J., & Lee, M. (2012) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2012.20.4.393 · Cited by 8
“, 1996), whose sustained activation has been implicated in a variety of cancers, including colon, lung, breast, and prostate cancers (Yeatman, 2004).”
BackgroundCo-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer
Rubio-Cuesta, B., Carretero-Puche, C., Llamas, P., Sarmentero, J., Gil-Calderon, B., Lens-Pardo, A., Antón-Pascual, B., Rubio-González, E., Cámara-Jurado, M., Salamanca, J., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03058-6 · Cited by 7
Cirotti, C., Girolamo, C. D., Taddei, I., Contadini, C., Massacci, G., Sacco, F., Bufalo, D. D., Salvatori, I., Valle, C., & Barilà, D. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01542-3 · Cited by 7
Li, Y., Lai, J., Ran, M., Yi, T., Zhou, L., Luo, J., Liu, X., Tang, X., Huang, M., Xie, X., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176548 · Cited by 7
Early emergence of negative regulation of the tyrosine kinase Src by the C-terminal Src kinase
Taskinen, B., Ferrada, E., & Fowler, D. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.811174 · Cited by 7
“Src plays an important regulatory role in a variety of cellular functions, and aberrant Src activity is linked to cancer (15, 16).”
BackgroundMicro RNA ‐137‐mediated Src oncogenic signaling promotes cancer progression
Kokuda, R., Watanabe, R., Okuzaki, D., Akamatsu, H., & Oneyama, C. (2018) · Genes to Cells · doi:10.1111/gtc.12610 · Cited by 9
In silico targeting of colony-stimulating factor-1 receptor: delineating immunotherapy in cancer
Azhar, Z., Grose, R. P., Raza, A., & Raza, Z. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00164 · Cited by 7
A renaissance for YES in cancer
Lapouge, M., & Meloche, S. (2023) · Oncogene · doi:10.1038/s41388-023-02860-x · Cited by 8
“This transition requires dephosphorylation of the C-terminal tyrosine and autophosphorylation of the activation loop [1, 7].”
BackgroundNovel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents
Alam, M. M., Lee, S.-C., Jung, Y., Yun, H. J., Min, H.-Y., Lee, H. J., Pham, P. C., Moon, J., Kwon, D. I., Lim, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5839 · Cited by 7
“…NSCLC cell lines and tumors in patients [18] and plays an important role in cancer cell survival and resistance to targeted anticancer therapies [50, 51], and cancer cells appear to display resistance to the IGF-1R-targeted agents through Src activation [17, 18], we postulated that dual…”
Doki, N., Kawashima, T., Nomura, Y., Tsuchiya, A., Oneyama, C., Akagi, T., Nojima, Y., & Kitamura, T. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01235.x · Cited by 8
Huo, X., Liao, Y., Tian, Y., Gao, L., & Cao, L. (2016) · RSC Advances · doi:10.1039/c6ra23443g · Cited by 7
Manchanda, P., Parshad, B., Kumar, A., Tiwari, R. K., Shirazi, A. N., Parang, K., & Sharma, S. K. (2017) · Archiv der Pharmazie · doi:10.1002/ardp.201600390 · Cited by 7
Bozhokina, E., Tsaplina, O. A., & Khaitlina, S. Y. (2019) · Biochemistry (Moscow) · doi:10.1134/s0006297919060099 · Cited by 7
Mokenapelli, S., Gutam, M., Yerrabelly, J. R., Irlapati, V. K., Gorityala, N., Sagurthi, S. R., & Chitneni, P. R. (2020) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162020050179 · Cited by 7
The tyrosine kinase v‐Src modifies cytotoxicities of anticancer drugs targeting cell division
Yuki, R., Hagino, M., Ueno, S., Kuga, T., Saito, Y., Fukumoto, Y., Yamaguchi, N., Yamaguchi, N., & Nakayama, Y. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16270 · Cited by 6
Small‐Molecule Inhibition of the UNC119–Cargo Interaction
Mejuch, T., Garivet, G., Hofer, W., Kaiser, N., Fansa, E. K., Ehrt, C., Koch, O., Baumann, M., Ziegler, S., Wittinghofer, A., et al. (2017) · Angewandte Chemie · doi:10.1002/ange.201701905 · Cited by 8
Clinical Relevance of Targeted Interference with Src-Mediated Signal Transduction Events
Ly, Q. P., & Yeatman, T. J. (2007) · Springer eBooks · doi:10.1007/978-3-540-31209-3_10 · Cited by 7
Self-citationTarget Identification of a 1,3,4‐Oxadiazin‐5(6H)‐One Anticancer Agent via Photoaffinity Labelling
Lim, B., Lee, J., Kim, B., Lee, R., Park, J., Oh, D., Gam, J., & Lee, J. (2019) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.201900258 · Cited by 7
Larroque‐Lombard, A., Na, N., Rao, S., Lauwagie, S., Halaoui, R., Coudray, L., Huang, Y. S., & Jean‐Claude, B. J. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12043 · Cited by 7
“In the latter process, receptor tyrosine kinases can interact with non-receptor tyrosine kinases to promote motility and invasion (1,2).”
BackgroundPicard, C., Gabert, J. A., Olive, D., & Collette, Y. (2004) · Leukemia · doi:10.1038/sj.leu.2403499 · Cited by 7
He, Y., Liu, J., Guo, B., Wáng, Y. X. J., Pan, X., Li, D., Tang, T., Yang, C., Peng, S., Bian, Z., et al. (2015) · Scientific Reports · doi:10.1038/srep08856 · Cited by 7
“Proto-oncogene tyrosine-protein kinase Src (encoded by the c-src gene) is a non-receptor tyrosine kinase localized to the cellular membrane, involved in the regulation of a range of cellular processes, including proliferation, adhesion, motility and survival 15 .”
BackgroundMaternal and zygotic requirements for src64 during Drosophila cellularization
Strong, T. C., & Thomas, J. H. (2011) · genesis · doi:10.1002/dvg.20783 · Cited by 7
“…of vertebrate c-src, a proto-oncogene encoding a nonreceptor tyrosine kinase that regulates adhesion, cell cycle progression, migration, apoptosis, development, angiogenesis, tumor invasion, and metastasis (Frame, 2002; Harrison, 2003; Thomas and Brugge, 1997; Tweedie et al., 2009; Yeatman, 2004).”
BackgroundOxidative modifications control aberrant tyrosine kinase activity
Schulan, P., Wende, K., von Woedtke, T., Weltmann, K., Bekeschus, S., & Clemen, R. (2024) · Biointerphases · doi:10.1116/6.0003970 · Cited by 6
Lindfors, H. E., Venkata, B. S., Drijfhout, J. W., & Ubbink, M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.01.026 · Cited by 6
“The SH2 and SH3 domains play a role both in regulating kinase activity and in recognition of substrates [5].”
BackgroundLi, Z., Xie, X., Tan, G., Xie, F., Liu, N., Li, W., & Sun, X. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00353 · Cited by 8
Kumbrink, J., Li, P., Pók-Udvari, Á., Klauschen, F., Kirchner, T., & Jung, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212364 · Cited by 7
“Other factors/mechanisms, such as enhanced integrin signaling [13], increasing c-Src activity in colorectal tumorigenesis [38], or alterations in the early growth response (EGR1)/NGFI-A binding protein (NAB2)/p130Cas network [23,35,39] may lead to constitutively active p130Cas limiting EREG expression.”
BackgroundNiraparib-induced STAT3 inhibition increases its antitumor effects
Zhao, Q., Kohut, A. Y., Li, Y., Martincuks, A., Austria, T., Zhang, C., Santiago, N. L., Borrero, R. M., Phan, X. T., Melstrom, L. G., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.966492 · Cited by 8
Phosphorylation of tyrosine 90 in SH3 domain is a new regulatory switch controlling Src kinase
Koudelková, L., Pelantová, M., Brůhová, Z., Sztacho, M., Pavlík, V., Pánek, D., Gemperle, J., Talacko, P., Brábek, J., & Rösel, D. (2023) · eLife · doi:10.7554/elife.82428 · Cited by 6
Zeng, G. H., Fang, D., Wu, W., Zhang, R., Xie, W., Wu, J. H., & Shen, Y. (2012) · International Journal of Quantum Chemistry · doi:10.1002/qua.24344 · Cited by 6
Broader implications of SILAC-based proteomics for dissecting signaling dynamics in cancer
Zhang, H., Xu, Y., Papanastasopoulos, P., Stebbing, J., & Giamas, G. (2014) · Expert Review of Proteomics · doi:10.1586/14789450.2014.971115 · Cited by 6
“Similarly, genome-wide characterization of miR-34a induced changes in CRC demonstrated that 228 proteins (113 down and 115 up) were altered in response to conditional miR-34a allele activation [60].”
BackgroundInfluentialCHK Methylation Is Elevated in Colon Cancer Cells and Contributes to the Oncogenic Properties
Zhu, S., Zhu, Y., Wang, Q., Zhang, Y., & Guo, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.708038 · Cited by 7
“Keywords: CHK, colon cancer, DNA methylation, FHC, drug resistance INTRODUCTION Src is an important oncogene that plays key roles in multiple signal transduction pathways (Yeatman, 2004).”
BackgroundSrc tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Rothschild, S. I., & Gautschi, O. P. (2012) · Clinical Investigation · doi:10.4155/cli.12.27 · Cited by 6
Wang, L., Yu, X., Dong, J., Meng, Y., Yang, Y., Wang, H., Wang, C., Zhang, Y., Zhao, Y., Zhao, J., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.111 · Cited by 6
Multiplex Analysis of Src Family Kinase Signaling by Microbead Suspension Arrays
Campbell, M., Lie, W., Zhao, J., Hayes, D., Mistry, J., Kung, H.-J., Luciw, P. A., & Khan, I. (2010) · Assay and Drug Development Technologies · doi:10.1089/adt.2009.0255 · Cited by 7
“28 As such, some members of this kinase family represent targets for drug discovery.”
c-src activating mutation analysis in Chinese patients with colorectal cancer
Tan, Y. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i15.2351 · Cited by 6
Molecular Therapeutics Lessons from the Role of Src in Cellular Signalling
Tuháčková, Z. (2005) · Folia Biologica · doi:10.14712/fb2005051040114 · Cited by 6
Metadata
- Authors
- Yeatman, T. J.
- Affiliations
- Moffitt Cancer Center (US)
- Corresponding author
- Yeatman, Timothy J.
- ORCID
- Yeatman, Timothy J.
- Venue
- Nature Reviews Cancer
- Published
- 2004-06-01
- Volume
- 4
- Issue
- 6
- Pages
- 470-480
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2036988959
- Cited by
- 1,113
- References
- 115
- Citations by year
- 2026: 17 · 2025: 21 · 2024: 20 · 2023: 43 · 2022: 43 · 2021: 46 · 2020: 44 · 2019: 39 · 2018: 49 · 2017: 44 · 2016: 69 · 2015: 56 · 2014: 72 · 2013: 79 · 2012: 73
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- Src kinase, non-receptor tyrosine kinase, cancer, metastasis, cell invasion, cell motility, cell proliferation, anticancer agents, tumor progression
- MeSH terms
- Antineoplastic Agents, Cell Division, Humans, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Phenotype, Gene Expression Regulation, Neoplastic, Genes, src, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.